Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 29Fluorouracil 23Capecitabine 19pembrolizumab 17Nivolumab 17Leucovorin 16Docetaxel 10Paclitaxel 9Drug Therapy 9Cisplatin 9Trastuzumab 8S 1 (combination) 8fludarabine 7Specimen Handling 7Cyclophosphamide 7trastuzumab deruxtecan 6Bevacizumab 6Magnetic Resonance Spectroscopy 5Biopsy 5zolbetuximab 4Irinotecan 4Carboplatin 4zimberelimab 3sintilimab 3olaparib 3fludarabine phosphate 3durvalumab 3atezolizumab 3aldesleukin 3XELOX 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × camrelizumab × 90 days × Clear all
NCT07320586 2026-03-13

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Shandong Tumor Hospital

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡